Schüler, Stephanie S. http://orcid.org/0000-0002-5879-2480
Petersen, Christian L. http://orcid.org/0000-0002-4840-275X
West, Nicholas C. http://orcid.org/0000-0001-8382-5136
Ansermino, J. Mark http://orcid.org/0000-0001-8427-2035
Merchant, Richard N. http://orcid.org/0000-0002-8526-2477
Görges, Matthias http://orcid.org/0000-0003-2193-178X
Article History
Received: 15 April 2020
Accepted: 21 July 2020
First Online: 25 July 2020
Compliance with ethical standards
:
: JMA has consulted for NeuroWave Systems Inc. JMA, RNM and MG are party to a licensing agreement between the University of British Columbia and NeuroWave Systems Inc. for control technology. JMA and RNM have received funds for research sponsored by NeuroWave Systems Inc. The remaining authors have no interests to declare. This study was supported by internal funds. NeuroWave Systems Inc. provided loan equipment and sensors for the original study.
: The Fraser Health research ethics board approval [FHREB 2016–054] approved the randomized ketamine trial (clinicaltrials.gov NCT02908945), which allowed secondary analysis of the EEG data collected, and the UBC C&W Research Ethics Board (H15-03244) granted permission for de-identified DoH monitor comparisons using EEG data replay.
: Written informed consent was obtained from all individual participants in the original study.